The University of Chicago Header Logo


Dejan Micic to Tumor Necrosis Factor-alpha

This is a "connection" page, showing publications Dejan Micic has written about Tumor Necrosis Factor-alpha.
Connection Strength

  1. Risk of Cancer Recurrence Among Individuals Exposed to Antitumor Necrosis Factor Therapy: A Systematic Review and Meta-Analysis of Observational Studies. J Clin Gastroenterol. 2019 01; 53(1):e1-e11.
    View in: PubMed
    Score: 0.128
  2. Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. Inflamm Bowel Dis. 2018 03 19; 24(4):849-860.
    View in: PubMed
    Score: 0.121
  3. Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases - authors' reply. Aliment Pharmacol Ther. 2017 05; 45(10):1372.
    View in: PubMed
    Score: 0.114
  4. Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-a agents in rheumatic diseases; A systematic review and meta-analysis. J Autoimmun. 2017 May; 79:4-16.
    View in: PubMed
    Score: 0.112
  5. Outcome of pregnancy and neonatal complications with anti-tumor necrosis factor-a use in females with immune mediated diseases; a systematic review and meta-analysis. J Autoimmun. 2017 01; 76:38-52.
    View in: PubMed
    Score: 0.111
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.